Home - Bioceltix

Product candidates

At Bioceltix, we create innovative, off the shelf medicines – our aim is to harness the potential of mesenchymal stem cells (MSCs). The active pharmaceutical ingredients of the developed product will not be limited to the cells themselves – they will also include the active biological substances produced by them.

News

2021.09.30

Information on the stock exchange trading

Please be advised that procedures connected with admission of Bioceltix S.A. shares to stock exchange trading are currently being finalized. ...

Read full

2021.09.10

Economic Forum in Karpacz

Łukasz Bzdzion, President of the Management Board, participated in the XXX Economic Forum in Karpacz on behalf of Bioceltix. The second day of ...

Read full

Investor relations

At Bioceltix, we develop innovative MSC-based biopharmaceuticals for use in companion animals. We target markets with high demand for effective pharmaceuticals.

Wrote about us

Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets using drugs with stem cells.

We are changing the veterinary therapy standards